Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, US-Based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed With Mycosis Fungoides or Sézary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07003100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07003100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, US-Based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed With Mycosis Fungoides or Sézary Syndrome and Treated With Standard of Care Mogamulizumab
Lead sponsor
City of Hope Medical Center
Phase
Observational
Overall status
Recruiting
Start date
December 6, 2024
Completion date
October 19, 2026
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent mycosis fungoides, recurrent sezary syndrome, refractory mycosis fungoides, refractory sezary syndrome, stage ib mycosis fungoides and sezary syndrome ajcc v8, stage iia mycosis fungoides and sezary syndrome ajcc v8, stage iib mycosis fungoides and sezary syndrome ajcc v8, stage iii mycosis fungoides and sezary syndrome ajcc v8, stage iv mycosis fungoides and sezary syndrome ajcc v8